Beijing Centergate Technologies

Beijing Centergate Technologies is a publicly traded Chinese conglomerate that has strategically pivoted its core business toward the healthcare and pharmaceutical sectors under its "Big Health" initiative. The company operates primarily through its flagship subsidiary, Beijing Zhongguancun Siping Pharmaceutical, which specializes in the development and manufacturing of chemical pharmaceuticals. Its commercial portfolio is heavily focused on therapeutic areas such as cardiovascular health, gastroenterology, and neuropsychiatry, featuring high-market-share products like rabeprazole sodium and amlodipine besylate. Beyond chemical drugs, the company also engages in traditional Chinese medicine and the management of medical device industrial parks, making it a multifaceted player in the Chinese domestic healthcare market.